Bioventus Inc. (Nasdaq: BVS) announced its financial results for the three and nine months ended September 26, 2026, in a Form 8-K filed on November 2, 2026. The company reported worldwide revenue of $142.4 million for the third quarter, representing a 3% increase compared to the prior-year period. Net income attributable to Bioventus was $6.0 million, up from $3.2 million in the prior year.
GAAP earnings per diluted share were $0.08, an improvement from $0.05 in the prior year. Non-GAAP earnings per diluted share were $0.17, reflecting a 13% increase from $0.15 in the prior year, driven by lower interest expense. Adjusted EBITDA for the quarter totaled $28.4 million, a 7% increase from $26.6 million in the prior year.
Revenue growth was driven by the Pain Treatments segment, which generated $71.3 million, a 6.2% increase. This growth was attributed to strong volume in hyaluronic acid therapy products, including Durolane, as well as platelet-rich plasma (PRP) and peripheral nerve stimulation (PNS) products. The Surgical Solutions segment reported revenue of $50.5 million, up 0.7%, supported by demand for Ultrasonics systems and disposables, though partially offset by softness in Bone Graft Substitutes (BGS). The Restorative Therapies segment, which includes the EXOGEN Bone Stimulation System, saw revenue decline 3.4% to $20.6 million.
Geographically, U.S. revenue increased 1.0% to $124.6 million, while international revenue grew 16.4% to $17.8 million, driven by strong volume growth in Pain Treatments and increased demand for Surgical Solutions.
Bioventus reported cash from operations of $20.7 million for the quarter. The company made a discretionary principal prepayment of $15.0 million on its term loan during the quarter, funded by operating cash flows. Bioventus reaffirmed its Adjusted EPS guidance for the full year 2026 of $0.75 to $0.79 per diluted share and updated its Net Sales guidance to $590 million to $595 million. The company also noted cash paid of $0.4 million during the three and nine months ended September 26, 2026, related to its review of potential strategic alternatives.
